48. Nam, Y.; Ramanishka, A.; Xu, Y.; Yasuda, R. M. H.; Nasburg, J. A.; Im, D.; Cui, M.; Chandy, K. G.; Wulff, H.; Zhang, M., Structural basis for the subtype-selectivity of KCa2.2 channel activators. Nat. Comm. 2026
47. Farmer, D. L.; Kumar, P.; Reynolds, E.; Lee, S. Y.; Powne, A. B.; Pivetti, C. D.; Zwienenberg, M.; McLennan, A. S.; Nolta, J. A.; Brown, E. G.; Saadai, P.; Hirose, S.; Wang, A., Feasibility and safety of cellular therapy for in-utero repair of myelomeningocele (CuRe Trial): a first-in-human, phase 1, single-arm study. Lancet. 2026 Feb
46. Kwun Nok Mimi, M.; Rougé, S. L. S.; Berumen, R. A.; Jacobi, A. A.; Weiner, J. C.; Naderi, S. Y.; Ireton, K. E.; Estrada-Tobar, Z. M.; Zeng, Z.; Martinez, J. M.; Xiang, Y. K.; Nieves-Cintrón, M.; Navedo, M. F.; Bartels, P.; Horne, M. C.; Hell, J. W., Stimulation of Ca2+ channel CaV1.2 activity by dopamine signaling augments spatial working memory. Sci. Signal. 2025.
45. Beckett, J. O. S.; Buzdygon, R.; Nguyen, S; Clark, A. A.; Schalk, S. S.; Svanholm, L. E. H.; Brasher, T. J.; Bazin, M.; Cuccurazzu, B.; Halberstadt, A. L.; McCorvy, J. D.; Mascal, M., Transforming Amino Acids into Serotonin 5-HT2A Receptor Ligands Using Photochemistry. JACS. 2025
44. Agrawal, R.; Gillie, D.; Mungenast, A.; Chytil, M.; Engel, S.; Wu, M. C.; Rasumussen, K.; Salinas, E.; Olson, D. E., Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics. ACS Chem. Neurosci. 2025
43. Hatzipantelis, C. J.; Liu, M.; Love, A.; Leventhal, S. J.; Maera, H.; Viswanathan, S.; Avetisyan, E.; Belinsky, L.; Rangel, M. M.; Jain, N. J.; Kelly, M.; Copeland, C.; Khatib, Y. A.; Fiehn, O.; Olson, D. E.; Stolzenberg, D. S., Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring. Nat. Comm. 2025.
42. Hatzipantelis, C. J.; Cameron L. P.; Liu, M.; Patel, S. D.; Saeger, H. N.; Vernier, A. M. M.; Khatib, Y. A.; Willis, B. J.; Lanoue, L.; Fiehn, O.; Olson, D. E. Indolethylamine N-Methyltransferase Deletion Impacts Mouse Behavior without Disrupting Endogenous Psychedelic Tryptamine Production. ACS Chem. Neurosci., 2025.
41. Aarrestad, I. K.; Cameron, L. P.; Fenton, E. M.; Casey, A. B.; Rijsketic, D. R.; Patel, S. D.; Sambyal, R.; Johnson, S. B.; Ly, C.; Viswanathan, J.; Barragan, E. V.; Lozano, S. A.; Seban, N.; Hu, H.; Powell, N. A.; Chytil, M.; Meyer, R.; Rose, D.; Hempel, C.; Olson, E.; Hansen, H. D.; Madsen, C. A.; Knudsen, G. M.; Redd, C.; Wheeler, D. G.; Guanzon, N.; Muir, J.; Hennessey, J. J.; Quon, G.; McCorvy, J. D.; Gandhi, S. P.; Rasmussen, K.; Liston, C.; Gray, J. A.; Heifets, B. D.; Nord, A. S.; Kim, C. K.; Olson, D. E. The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation. Nat. Neurosci., 2025.
40. Tuck, J. R.; Dunlap, L.E.; Khatib, Y. A.; Hatzipantelis, C. J.; Novak, S. W.; Rahn, R. M.; Davis, A. R.; Mosswood, A.; Vernier, A. M. M.; Fenton, E. M.; Aarrestad, I. K.; Tombari, R. J.; Carter, S. J.; Deane, Z.; Wang, Y.; Sheridan, A.; Gonzalez, M. A.; Avanes, A. A.; Powell, N. A.; Chytil; M.; Engel, S.; Fettinger, J. C.; Jenkins, A. R.; Carlezon Jr.; W. A.; Nord, A. S.; Kangas, B. D.; Rasmussen, K.; Liston, C.; Manor, U.; Olson, D.E. Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential. Proc. Natl. Acad. Sci. U.S.A. 2025. 122(16).
39. Iyer, R.N; Favela, D.; Domokos, A.; Zhang, G.; Avanes, A. A.; Carter, S. J.; Basargin, A. G.; Davis, A. R.; Tantillo, D. J.; Olson, D. E. Efficient and modular synthesis of ibogaine and related alkaloids. Nat. Chem. 2025.
38. Olson, D. E. Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity. Am. J. Psychiatry, 2024, 182(1): 10-12.
37. Muir, J., Lin, S., Aarrestad, I. K., Daniels, H. R., Ma, J., Tian, L., Olson, D. E., Kim, C. K. Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states. Science, 2024.
36. Bonilla, J., Giannotti, G., Kregar, N. P., Heinsbroek, J. A., Olson, D. E., Peters, J. The psychedelic drug DOI reduces heroin motivation by targeting 5-HT2A receptors in a heroin and alcohol co-use model. Neuropharmacology, 2024.
35. Zhang, R.; Anguiano, M.; Aarrestad, I. K.; Lin, S.; Chandra, J.; Vadde, S. S.; Olson, D. E., Kim, C. K. Rapid, Biochemical Tagging of Cellular Activity History in Vivo. Nat. Methods., 2024.
34. Warren, H. T.; Chow, W. L.; Chytil, M.; Rasmussen, K.; Olson, D. E. Identification of Psychoplastogenic Tropanes Lacking Muscarinic Activity. J. Med. Chem., 2024.
33. Warren, H. T.; Saeger, H. N.; Tombari, R. J.; Chytil, M.; Rasmussen, K.; Olson, D. E. Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer’s Disease. J. Med. Chem., 2024, 67, 6922–6937.
32. Hatzipantelis, C.J.; Olson, D.E. The Effects of Psychedelics on Neuronal Physiology, Annual Review of Physiology, 2023.
31. Chow, W. L.; Gonzalez, M. A.; Avanes, A. A.; Olson, D. E. Rapid Synthesis of Psychoplastogenic Tropane Alkaloids. JACS Au., 2023, 3, 2703–2708.
30. Tuck, J.R.; Dunlap, L.E.; Olson, D.E. Synthetic Strategies toward Lysergic Acid Diethylamide: Ergoline Synthesis via α-Arylation, Borrowing Hydrogen Alkylation, and C–H Insertion. ACS Chemical Neuroscience, 2023.
29. Wallace, R.; Olson, D.E.; Hooker, J.M. Neuroplasticity: The Continuum of Change, ACS Chemical Neuroscience, 2023, 14, 18, 3288–3290
28. Heifets, B.D.; Olson, D.E. Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacology, 2023.
27. Heinsbroek, J.A.; Giannotti, G.; Bonilla, J.; Olson, D.E.; Peters, J. Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model, Psychedelic Medicine, 2023, 1(2): 111-119.
26. Vargas, M.V.; Dunlap, L.E.; Dong, C.; Carter, S.J.; Tombari, R.J.; Jami, S.A.; Cameron, L.P.; Patel, S.D.; Hennessey, J.; Saeger, H.N.; McCorvy, J.D.; Gray, J.A,; Tian, L.; and Olson, D.E. Psychedelics promote neuroplasticity through activation of intracellular 5-HT2A receptors, Science, 2023, 379(6633): 700-706.
25. Cameron, L.P.; Patel, S.D.; Vargas, M.V.; Barragan, E.V.; Saeger, H.N.; Warren, H.T.; Chow, W.L.; Gray, J.A.; and Olson, D.E. 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines, ACS Chemical Neuroscience, 2023, 14(3): 351-358. PDF
24. Grieco, S. F.; Castrén, E.; Knudsen, G. M.; Kwan, A. C.; Olson, D. E.; Zuo, Yi.; Holmes, T. C.; Xu, X. Psychedelics and Neural Plasticity: Therapeutic Implications. J. Neurosci., 2022, 42, 8439–8449.
23. Kwan, A. C.; Olson, D. E.; Preller, K. H.; Roth, B. L. The Neural Basis of Psychedelic Action. Nat. Neurosci., 2022, 25, 1407–1419.
22. Olson, D. E. Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. Biochemistry, 2022, 61, 127–136.
21. Saeger, H. N.; Olson, D. E. Psychedelic-Inspired Approaches for Treating Neurodegenerative Disorders. J. Neurochem., 2022, 162, 109–127.
20. Vargas, M. V.; Meyer, R.; Avanes, A.; Rus, M.; Olson, D. E. Psychedelics and Other Psychoplastogens for Treating Mental Illness. Front. Psychiatry, 2021.
19. Cameron, L. P.; Olson, D. E. The Evolution of the Psychedelic Revolution. Neuropsychopharmacology, 2022, 47, 413–414.
18. Peters, J.; Olson, D. E. Engineering Safer Psychedelics for Treating Addiction. Neuroscience Insights, 2021, 16.
17. Lu, Ju.; Tjia, M.; Mullen, B.; Cao, B.; Łukasiewicz, K.; Shah-Morales, S.; Weiser, S.; Cameron, L. P.; Olson, D. E.; Chen, L.; Zuo, Y. An Analog of Psychedelics Restores Functional Neural Circuits Disrupted by Unpredictable Stress. Mol. Psychiatry, 2021, 26, 6237–6252.
16. Dong, C.; Ly, C.; Dunlap, L. E.; Vargas, M. V.; Sun, J.; Hwang, I.-W.; Azinfar, A.; Oh, W. C.; Wetsel, W. C.; Olson, D. E.; Tian, L. Psychedelic-Inspired Drug Discovery Using an Engineered Biosensor. Cell, 2021, 184, 2779–2792.
15. Olson, D. E. The Promise of Psychedelic Science. ACS Pharmacol. Transl. Sci., 2021, 4, 413–414.
14. Olson, D. E. The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol. Transl. Sci., 2020, 4, 563–567.
13. Cameron, L. P.; Tombari, R. J.; Lu, J.; Pell, A. J.; Hurley, Z. Q.; Ehinger, Y.; Vargas, M. V.; McCarroll, M. N.; Taylor, J. C.; Myers-Turnbull, D.; Liu, T.; Yaghoobi, B.; Laskowski, L. J.; Anderson, E. I.; Zhang, G.; Viswanathan, J.; Brown, B. M.; Tjia, M.; Dunlap, L. E.; Rabow, Z. T.; Fiehn, O.; Wulff, H.; McCorvy, J. D.; Lein, P. J.; Kokel, D.; Ron, D.; Peters, J.; Zuo, Y.; Olson, D. E. A Non-Hallucinogenic Psychedelic Analogue with Therapeutic Potential. Nature, 2021, 589, 474–479.
12. Ly, C.; Greb, A. C.; Vargas, M. V.; Duim, W. C.; Grodzki, A. C. G.; Lein, P. J.; Olson, D. E. Transient Stimulation with Psychoplastogens is Sufficient to Initiate Neuronal Growth. ACS Pharmacol. Transl. Sci., 2021, 4, 452–460.
11. Iyer, R. N.; Favela, D.; Zhang, G.; Olson, D. E. The Iboga Enigma: The Chemistry and Neuropharmacology of Iboga Alkaloids and Related Analogs. Nat. Prod. Rep., 2021, 38, 307–329.
10. Ly, C.; Shimizu, A. J.; Vargas, M. V.; Duim, W. C.; Wender, P. A.; Olson, D. E. Bryostatin 1 Promotes Synaptogenesis and Reduces Dendritic Spine Density in Cortical Cultures Through a PKC-Dependent Mechanism. ACS Chem. Neurosci., 2020, 11, 1545–1554.
9. Cameron, L. P.; Nazarian, A.; Olson, D. E. Psychedelic Microdosing: Prevalence and Subjective Effects. J. Psychoactive Drugs, 2020, 52, 113–122.
8. Dunlap, L. E.; Azinfar, A.; Ly, C.; Cameron, L. P.; Viswanathan, J.; Tombari, R. J.; Myers-Turnbull, D.; Taylor, J. C.; Grodzki, A. C.; Lein, P. J.; Kokel, D.; Olson, D. E. Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogs Through Structure-Activity Relationship Studies. J. Med. Chem., 2020, 63, 1142–1155.
7. Cameron, L. P.; Benson, C. J.; DeFelice, B. C.; Fiehn, O.; Olson, D. E. Chronic, Intermittent Microdoses of the Psychedelic N,N‐Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chem. Neurosci., 2019, 10, 3261−3270.
6. Olson, D. E. Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. J. Exp. Neurosci. 2018, 12, 1–4.
5. Cameron, L. P.; Olson, D. E. Dark Classics in Chemical Neuroscience: N,N-Dimethyltryptamine (DMT). ACS Chem. Neurosci., 2018, 9, 2344–2357.
4. Dunlap, L. E.; Andrews, A. A.; Olson, D. E. Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine. ACS Chem. Neurosci., 2018, 9, 2408–2427.
3. Ly, C.; Greb, A. C.; Cameron, L. P.; Wong, J.; Barragan, E.; Wilson, P.; Burbach, K. F.; Dunlap, L. E.; Soltanzadeh Zarandi, S.; Sood, A.; Duim, W. C.; Paddy, M. R.; Dennis, M.; McAllister, A. K.; Ori-McKenney, K. M.; Gray, J. A.; Olson, D. E. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018, 23, 3170–3182.
2. Dunlap, L. E.; Olson, D. E. Reaction of N,N-Dimethyltryptamine with Dichloromethane Under Common Experimental Conditions. ACS Omega, 2018, 3, 4968–4973.
1. Cameron, L. P.; Benson, C. J.; Dunlap, L. E.; Olson, D. E. Effects of N,N-dimethyltryptamine (DMT) on rat behaviors relevant to anxiety and depression. ACS Chem. Neurosci. 2018, 9, 1582–1590.
